Porton Advanced Solutions, a cell and gene therapy contract development and manufacturing organization (CDMO), has signed an agreement with Suzhou Royaltech Med Co., Ltd., to promote the establishment of microbial vectors used for gene therapy (MVGTs) and mRNA drug platform technology, as well as accelerate the R&D process of innovative biopharmaceuticals. Porton Advanced provides an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, gene therapy, onco...